NATCO announces approval of its ANDA for Cabazitaxel Intravenous Solution

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces today that the U.S. Food and Drug Administration has granted approval to its partner Breckenridge Pharmaceutical Inc's Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit®) for the 60mg/1.5mL (40mg/mL) strength.

Breckenridge and Natco are unable to make further comment regarding the launch date for the product, as that is confidential and cannot be disclosed at this time. According to industry sales data, Jevtana Kit generated annual sales of $303 million during the twelve months ending May 2022.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 655.10 as compared to the previous close of Rs. 656.15. The total number of shares traded during the day was 8349 in over 982 trades.

The stock hit an intraday high of Rs. 669.00 and intraday low of 653.35. The net turnover during the day was Rs. 5499763.00.

*All brand names and trademarks are the property of their respective owners

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 BreckenridgePharmaceuticals ANDA Approval USFDA CabazitaxelIntravenousPowder